![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADAMTS10 |
Gene summary for ADAMTS10 |
![]() |
Gene information | Species | Human | Gene symbol | ADAMTS10 | Gene ID | 81794 |
Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 10 | |
Gene Alias | ADAM-TS10 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q6ZN14 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81794 | ADAMTS10 | male-WTA | Human | Thyroid | PTC | 1.09e-02 | 7.70e-02 | 0.1037 |
81794 | ADAMTS10 | ATC13 | Human | Thyroid | ATC | 6.99e-29 | 5.22e-01 | 0.34 |
81794 | ADAMTS10 | ATC5 | Human | Thyroid | ATC | 4.31e-39 | 5.56e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAMTS10 | SNV | Missense_Mutation | rs782280501 | c.629G>A | p.Arg210Gln | p.R210Q | protein_coding | tolerated(0.1) | benign(0.232) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ADAMTS10 | SNV | Missense_Mutation | rs368775657 | c.1889N>T | p.Thr630Met | p.T630M | protein_coding | deleterious(0) | possibly_damaging(0.79) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ADAMTS10 | SNV | Missense_Mutation | novel | c.3258N>A | p.Phe1086Leu | p.F1086L | protein_coding | deleterious(0.01) | possibly_damaging(0.805) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
ADAMTS10 | SNV | Missense_Mutation | rs527419015 | c.556N>T | p.Arg186Cys | p.R186C | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
ADAMTS10 | SNV | Missense_Mutation | c.2303N>A | p.Arg768His | p.R768H | protein_coding | tolerated(0.08) | possibly_damaging(0.618) | TCGA-FI-A2F9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ADAMTS10 | SNV | Missense_Mutation | rs377333794 | c.1132G>A | p.Val378Ile | p.V378I | protein_coding | tolerated(1) | benign(0.001) | TCGA-CC-5260-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ADAMTS10 | SNV | Missense_Mutation | c.2624N>A | p.Arg875Lys | p.R875K | protein_coding | tolerated(0.73) | benign(0.003) | TCGA-DD-A11D-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | ||
ADAMTS10 | SNV | Missense_Mutation | c.2513N>G | p.Ser838Trp | p.S838W | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-DD-A4NV-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | ||
ADAMTS10 | SNV | Missense_Mutation | novel | c.1114N>T | p.Arg372Cys | p.R372C | protein_coding | deleterious(0.03) | probably_damaging(0.972) | TCGA-DD-AAW3-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADAMTS10 | SNV | Missense_Mutation | novel | c.1700N>G | p.Val567Gly | p.V567G | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-05-4390-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |